Althera to showcase cardio-metabolic pipeline at CPHI South East Asia 2026

Althera Laboratories will present its expanding cardiovascular and metabolic portfolio at CPHI South East Asia 2026 in Bangkok from July 8-10, using Booth C08 to court regional licensing partners. The company says the event will help advance out-licensing discussions in a market facing rising demand for chronic disease treatments. Why it matters: - Althera Laboratories is using CPHI South East Asia 2026 to push deeper into a region where cardiovascular and metabolic disease burdens are rising. - The Bangkok event gives Althera a direct channel to regional stakeholders and potential licensing partners. - The company is positioning its fixed-dose combinations as tools to improve adherence and simplify long-term treatment. What happened: - Althera Laboratories Limited announced a planned exhibition at CPHI South East Asia 2026 in Bangkok, Thailand. - The event runs from July 8 to July 10, 2026, at the Queen Sirikit National Convention Center. - Althera will occupy a 30-square-meter space at Booth C08. - The company’s global licensing team will meet with industry leaders, regional stakeholders and potential partners at the booth. The details: - Althera will discuss regional partnerships for its product portfolio and its pipeline of value-added fixed-dose combinations. - The company describes those treatments as designed to improve patient adherence, simplify treatment regimens and support better clinical outcomes in chronic cardiovascular and metabolic care. - Althera says the exhibition reflects its commitment to expanding in emerging markets. - Mathieu Da Luz, head of business development at Althera Laboratories, said the company’s growth over the past year, including expanded product reach and partnerships in Europe and the Middle East, positions it to address unmet healthcare needs in South East Asia. - Da Luz said CPHI Bangkok offers a platform to connect with regional leaders and build strategic alliances. - Da Luz said Althera can offer high-quality, value-added medicines supported by scientific evidence and a global supply network. Between the lines: - The booth strategy suggests Althera is prioritizing out-licensing and partnership building over a broad consumer-facing launch. - South East Asia appears to be a target growth market for the company’s cardio-metabolic portfolio. - Althera is pairing a regional trade show appearance with a broader pitch around scientific backing and supply reliability. What’s next: - Althera will use the July 8-10 conference window to pursue discussions with potential licensing partners. - Professionals attending CPHI South East Asia are being directed to Booth C08 for meetings with the licensing team. - Future agreements or regional rollout plans were not announced. The bottom line: - Althera is turning CPHI South East Asia 2026 into a partnership-scouting event for its expanding cardiovascular and metabolic pipeline.